Traceable reference dosimetry in MRI guided radiotherapy using alanine: calibration and magnetic field correction factors of ionisation chambers.

Abstract

Magnetic resonance imaging (MRI)-guided radiotherapy (RT) (MRIgRT) falls outside the scope of existing high energy photon therapy dosimetry protocols, because those protocols do not consider the effects of the magnetic field on detector response and on absorbed dose to water. The aim of this study is to evaluate and demonstrate the traceable measurement of absorbed dose in MRIgRT systems using alanine, made possible by the characterisation of alanine sensitivity to magnetic fields reported previously by Billaset al(2020Phys. Med. Biol.65115001), in a way which is compatible with existing standards and calibrations available for conventional RT. In this study, alanine is used to transfer absorbed dose to water to MRIgRT systems from a conventional linac. This offers an alternative route for the traceable measurement of absorbed dose to water, one which is independent of the transfer using ionisation chambers. The alanine dosimetry is analysed in combination with measurements with several Farmer-type chambers, PTW 30013 and IBA FC65-G, at six different centres and two different MRIgRT systems (Elekta Unity™ and ViewRay MRIdian™). The results are analysed in terms of the magnetic field correction factors, and in terms of the absorbed dose calibration coefficients for the chambers, determined at each centre. This approach to reference dosimetry in MRIgRT produces good consistency in the results, across the centres visited, at the level of 0.4% (standard deviation). Farmer-type ionisation chamber magnetic field correction factors were determined directly, by comparing calibrations in some MRIgRT systems with and without the magnetic field ramped up, and indirectly, by comparing calibrations in all the MRIgRT systems with calibrations in a conventional linac. Calibration coefficients in the MRIgRT systems were obtained with a standard uncertainty of 1.1% (Elekta Unity™) and 0.9% (ViewRay MRIdian™), for three different chamber orientations with respect to the magnetic field. The values obtained for the magnetic field correction factor in this investigation are consistent with those presented in the summary by de Pooteret al(2021Phys. Med. Biol.6605TR02), and would tend to support the adoption of a magnetic field correction factor which depends on the chamber type, PTW 30013 or IBA FC65-G.